Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Jung Yong | - |
dc.contributor.author | Seo, Ja-Young | - |
dc.contributor.author | Kim, Sun-Hee | - |
dc.contributor.author | Jung, Hyun Ae | - |
dc.contributor.author | Park, Silvia | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Jung, Chul Won | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Park, Joon Seong | - |
dc.contributor.author | Kim, Hee-Jin | - |
dc.contributor.author | Jang, Jun Ho | - |
dc.date.available | 2020-02-28T09:44:05Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-05 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10586 | - |
dc.description.abstract | Background: Hypomethylating agents, such as azacitidine and decitabine, now constitute one of the mainstays of myelodysplastic syndrome (MDS) treatment. In recent years, novel recurrent mutations in multiple genes encoding RNA spliceosomal machinery (SRSF2, U2AF1, ZRSR2, SF3B1) were revealed. However, the clinical impact of these mutations on the outcomes of treatment of MDS patients with hypomethylating agents has not been described. Patients and Methods: A total of 58 de novo MDS patients were included in the study who had received first-line decitabine treatment. Polymerase chain reaction (PCR) followed by direct sequencing analyses was performed for the spliceosomal machinery genes including SRSF2, U2AF1 and ZRSR2. Results: In the present analysis of 58 Korean MDS patients, mutations in the splicing machinery genes SRSF2, | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | INT INST ANTICANCER RESEARCH | - |
dc.relation.isPartOf | ANTICANCER RESEARCH | - |
dc.subject | RING SIDEROBLASTS | - |
dc.subject | SF3B1 MUTATIONS | - |
dc.subject | AZACITIDINE | - |
dc.subject | EXPERIENCE | - |
dc.subject | STABILITY | - |
dc.subject | NEOPLASMS | - |
dc.subject | SURVIVAL | - |
dc.subject | PATHWAY | - |
dc.title | Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000354267200079 | - |
dc.identifier.bibliographicCitation | ANTICANCER RESEARCH, v.35, no.5, pp.3081 - 3089 | - |
dc.identifier.scopusid | 2-s2.0-84929672547 | - |
dc.citation.endPage | 3089 | - |
dc.citation.startPage | 3081 | - |
dc.citation.title | ANTICANCER RESEARCH | - |
dc.citation.volume | 35 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Seo, Ja-Young | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Myelodysplastic syndrome | - |
dc.subject.keywordAuthor | SRSF2 | - |
dc.subject.keywordAuthor | U2AF1 | - |
dc.subject.keywordAuthor | ZRSR2 | - |
dc.subject.keywordAuthor | decitabine | - |
dc.subject.keywordPlus | RING SIDEROBLASTS | - |
dc.subject.keywordPlus | SF3B1 MUTATIONS | - |
dc.subject.keywordPlus | AZACITIDINE | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | STABILITY | - |
dc.subject.keywordPlus | NEOPLASMS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.